ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Clinical trials for ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS explained in plain language.
Never miss a new study
Get alerted when new ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS trials appear
Sign up with your email to follow new studies for ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise for tough kidney diseases
Disease control OngoingThis study tests a new drug called povetacicept in adults with certain autoimmune kidney diseases, including lupus nephritis and IgA nephropathy. The goal is to see if the drug is safe and can help control the disease. Participants receive the drug every 4 weeks for at least 6 mo…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1, PHASE2 • Sponsor: Alpine Immune Sciences, Inc. • Aim: Disease control
Last updated Jun 22, 2026 12:07 UTC
-
Experimental Donor-Cell therapy takes aim at tough autoimmune diseases
Disease control OngoingThis early-stage study tests a therapy called SC291, made from donor immune cells, in 7 people with severe lupus or vasculitis that hasn't improved with standard treatments. The goal is to see if it is safe and tolerable, and to get a first look at whether it can control the dise…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated Jun 22, 2026 12:01 UTC
-
Kidney failure patients may ditch immune drugs in landmark trial
Disease control OngoingThis study looks at whether people with ANCA vasculitis who have reached end-stage kidney disease can safely stop taking immunosuppressive medications. The goal is to see if stopping these drugs lowers the risk of serious infections and other side effects without causing dangerou…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE3 • Sponsor: Centre Hospitalier Departemental Vendee • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC